Trial Profile
A 3-year cohort study to evalaute the efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in patients with pneumococcal and vaccine type community-acquired pneumonia
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- 04 May 2018 New trial record
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases